Pliant Therapeutics, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Bernard Coulie
- Full Time Employees
- 49
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 331 Oyster Point Boulevard South San Francisco CA United States of America 94080
- IPO Date
- Jun 3, 2020
- CIK
- 0001746473
- Website
- pliantrx.com
- Similar Companies
- Business
- Pliant Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel therapies for the treatment of fibrotic diseases. The company specializes in integrin biology and TGF-β pathway modulation to develop tissue-specific, orally administered small molecule therapeutics aimed at halting or reversing fibrosis across multiple organs. Its main products include bexotegrast (PLN-74809), a dual αvβ6/αvβ1 integrin inhibitor formerly in Phase 2b/3 trials for idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC); PLN-1474, an αvβ1 integrin inhibitor targeting liver fibrosis associated with nonalcoholic steatohepatitis (NASH); and PLN-101095, an αvβ8 integrin inhibitor in early-stage trials for solid tumors. The company also has a preclinical monoclonal antibody, PLN-101325, targeting integrin α7β1 for muscular dystrophies. Operating primarily in the United States with clinical programs extending internationally, Pliant is headquartered in South San Francisco, California, and was founded in 2015. Recent major developments include the discontinuation of bexotegrast development for IPF due to unfavorable risk-benefit outcomes observed in late-stage trials, leading to corporate restructuring focused on late-stage clinical trial execution. Pliant continues to advance PLN-101095, with promising interim Phase 1 data expected to be fully reported by the end of 2025. The company received regulatory clearance for a Phase 1 study of PLN-101325, expanding its pipeline into neuromuscular indications. Additionally, Pliant maintains a strategic collaboration and licensing agreement with Novartis for the development and commercialization of PLN-1474 and up to three other integrin targets, with Novartis assuming responsibility for later-stage development and commercialization while providing funding and milestone payments to Pliant. The company actively participates in industry conferences such as the Piper Sandler Healthcare Conference and the American Thoracic Society International Conference to present clinical data and corporate updates. Pliant targets patient populations with fibrotic diseases including IPF, PSC, NASH-related liver fibrosis, and solid tumors, addressing significant unmet medical needs with precision integrin-targeted therapies. The company integrates its expertise in fibrosis biology, chemistry, and technology to innovate in tissue-specific drug delivery and internalization. With its focused pipeline and strategic partnerships, Pliant Therapeutics positions itself as a leading biotechnology firm in the fibrosis treatment segment, aiming to transform therapeutic options for patients worldwide through its specialized integrin-targeted drug candidates and ongoing clinical development efforts. This description reflects Pliant Therapeutics' current operations, product portfolio, recent strategic changes, and clinical development focus as of late 2025.
Company News
Pliant Therapeutics Appoints Craig Blanchette, Ph.D., as Senior Vice President, Research (siRNA)
Pliant Therapeutics Announces Upcoming Presentation at European Society for Medical Oncology Congress 2026
Pliant Therapeutics Appoints David Raben, M.D., as Chief Medical Officer
Reviewing Pliant Therapeutics (NASDAQ:PLRX) & Black Diamond Therapeutics (NASDAQ:BDTX)
Connor Clark & Lunn Investment Management Ltd. Makes New $611,000 Investment in Pliant Therapeutics, Inc. $PLRX
Pliant Therapeutics Receives FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatment of ICI-Refractory Solid Tumors
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
Pliant Therapeutics Names Flavia Borellini, Ph.D. and Robert Iannone, M.D.
Pliant Therapeutics, Inc. (PLRX) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Pliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
Pliant Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference
Pliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid Tumors
Pliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 AACR Annual Meeting
Pliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 AACR Annual Meeting
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Given Consensus Recommendation of “Reduce” by Analysts
Head-To-Head Review: Pliant Therapeutics (NASDAQ:PLRX) versus Dermata Therapeutics (NASDAQ:DRMA)
Pliant Therapeutics Announces Upcoming Presentation of Phase 1 Clinical Trial of PLN-101095 in Patients with Solid Tumors at the 2026 AACR Annual Meeting
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2025 Financial Results
Stock Picks From Seeking Alpha's February 2026 New Analysts